Budget Range
Min
€1,500
Average
€35,230
Max
€201,903
Role Distribution
Sector Distribution
Budget by Sector (€)
Projects (29)
P
Advancing Clinical Care and Equity through Scalable Solutions in Alzheimer’s Disease diagnosis and treatment
Health101253010
€201,903
P
Personalized disease prediction and prevention in chronic inflammatory disorders
Health101156542
€110,002
C
The pandemic within: tackling brain vulnerability in COVID19 at high resolution: NEUROCOV
Health101057775
€83,840
P
Accelerating the Validation of Predictive Liquid Biomarkers for Frontotemporal Dementia Diagnosis and Subclassification
Health101156175
€79,949
P
Development, optimisation and implementation of artificial intelligence methods for real world data analyses in regulatory decision-making and health technology assessment along the product lifecycle
Health101095353
€69,994
P
PRECISION MEDICINE PLATFORM IN NEURODEGENERATIVE DISEASE
Health101112145
€60,698
P
Beyond neuroInflammation: new Concepts to Elucidate the immune system’s vital role in Parkinson’s disease
MSCA (Marie Skłodowska-Curie)101167843
€39,469
P
BRaIn Disease monitoring throuGh the lifE span powered by Artificial Intelligence
MSCA (Marie Skłodowska-Curie)101225642
€36,269
P
A synaptic mechanogenetic technology to repair brain connectivity
HORIZON.3.1101099579
€35,440
P
Technology-driven combinatorial therapy to rewire the spinal cord after injury
MSCA (Marie Skłodowska-Curie)101073374
€26,668
P
FuEl ThE bRaiN In healtThY aging and agE-relateD diseases
MSCA (Marie Skłodowska-Curie)101072759
€26,293
P
NAD+ International Scientist-training
MSCA (Marie Skłodowska-Curie)101073251
€25,308
C
Kinase Regulation by Phase Separation
HORIZON.1.1101141570
€24,999
C
Advancing a vaccine targeting genetic amyotrophic lateral sclerosis (C9orf72 ALS) to the clinical stage
European Innovation Council101057649
€24,998
C
Targeting rogue DNA repair and genomic instability as novel toxicity mechanisms in C9orf72 ALS/FTD
HORIZON.1.1101201672
€24,989
P
Re-Defining early Parkinson’s disease
ERC (European Research Council)101169580
€24,637
C
Tau, a molecular modulator of neuronal energy managment
ERC (European Research Council)101126140
€21,949
C
Decoding neuropeptide function in inhibitory amygdala microcircuits
ERC (European Research Council)101171621
€19,996
C
Understanding the impact of environmental POLlution on the adaptive Immune System
HORIZON.1.1101163024
€14,997
C
Interface between Membraneless Organelles and Membranes
HORIZON.1.1101078172
€14,996
C
Do T cells link loss and gain-of-function mechanism in C9orf72 ALS/FTD?
HORIZON.1.1101117710
€14,986
C
Tandem Repeats Associated with Neurogenomic Somatic Instability and Neurodegeneration
HORIZON.1.1101041677
€14,956
P
Bringing Intrinsically Disordered Proteins to Biomedical Applications
Widening Participation101160233
€12,447
P
A drug screen for enhancers of adult neurogenesis in ageing: Drosophila as a new translationally-relevant platform
MSCA (Marie Skłodowska-Curie)101107384
€2,371
P
The role of eEF1A in synapse function, maintenance, and synucleinopathy
MSCA (Marie Skłodowska-Curie)101062581
€2,359
C
Phase separation in Alzheimer's disease and Phase-separated c-Abl dynamics
MSCA (Marie Skłodowska-Curie)101205252
€2,180
C
Mechanism of protein kinases in biomolecular condensates
MSCA (Marie Skłodowska-Curie)101148056
€1,738
P
Functional analysis of TSPAN14 as a genetic risk factor for Alzheimer’s disease
MSCA (Marie Skłodowska-Curie)101105827
€1,738
C
Repurposing a human drug to treat Alzheimer’s disease
ERC (European Research Council)101069214
€1,500